Triple-Gene Announces Completion of Enrollment and Dosing in Phase 1 Trial of INXN‑4001, First Multigenic Investigational Therapeutic Candidate for Treatment of Heart Failure
- Thursday, November 7, 2019, 7:53
- PR Newswire
- Add a comment
GERMANTOWN, Md., Nov. 7, 2019 /PRNewswire/ — Triple-Gene LLC, a clinical stage cardiovascular gene therapy company and majority owned subsidiary of Intrexon Corporation (NASDAQ: XON), today announced the completion of enrollment and dosing in its Phase 1 trial of INXN-4001, a multigenic…
About the Author
admin has written 20652 stories on this site.